<DOC>
	<DOCNO>NCT00107354</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , cellular adoptive immunotherapy , stimulate immune system different way stop cancer cell grow . PURPOSE : This phase I trial study side effect cellular adoptive immunotherapy treat patient acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome relapse donor stem cell transplant .</brief_summary>
	<brief_title>Cellular Adoptive Immunotherapy Treating Patients With Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxic effect adoptive immunotherapy comprise CD8-positive minor histocompatability antigen-specific cytotoxic T-lymphocytes patient acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome relapse allogeneic hematopoietic stem cell transplantation . Secondary - Determine persistence adoptively transfuse T cell vivo assess migration bone marrow patient . - Determine anti-leukemic activity therapy patient . OUTLINE : This pilot , open-label , nonrandomized study . - Leukapheresis : Patients undergo leukapheresis obtain peripheral blood mononuclear cell ( PBMCs ) transplantation . Donors undergo leukapheresis obtain PBMCs use feeder cell generate adoptive immunotherapy . Patient PBMCs combine donor PBMCs expand vitro generate CD8-positive minor histocompatability antigen-specific cytotoxic T-lymphocytes ( CTLs ) adoptive immunotherapy . - Transplantation : Patients undergo allogeneic bone marrow peripheral blood stem cell transplantation . Patients morphologic flow cytometric relapse day 100 post-transplantation proceed cytoreductive chemotherapy . Patients molecular cytogenetic relapse day 100 post-transplantation proceed directly adoptive immunotherapy . Patients relapsed disease day 100 post-transplantation eligible receive adoptive immunotherapy later date provide patient continue relapse CTLs available . - Cytoreductive chemotherapy : The chemotherapy regimen patient determine consideration prior chemotherapy , type leukemia , clinical parameter . Two regimen consider : - Mitoxantrone IV etoposide IV day -6 -2 - High-dose cytarabine IV 2 hour twice daily day -6 , -4 , -2 Patients achieve complete remission completion cytoreductive chemotherapy proceed adoptive immunotherapy . - Adoptive immunotherapy : Within 2-3 day completion cytoreductive chemotherapy , patient receive CTLs IV 1-2 hour day 0 , 4 , 11 , 21 , 28 absence unacceptable toxicity . Patients evidence persistent disease day 35 OR relapse disease initial response CTLs receive sixth infusion CTLs follow , 24 hour later , interleukin-2 subcutaneously daily 14 total dos absence unacceptable toxicity . Patients subsequent relapsed disease day 48 may eligible retreatment . After completion study treatment , patient follow bone marrow aspiration every 3 month 1 year . PROJECTED ACCRUAL : A total 25-30 patient ( 10-15 acute myeloid leukemia myelodysplastic syndrome AND 10-15 acute lymphoblastic leukemia ) accrue study within 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Undergoing allogeneic hematopoietic stem cell transplantation* major histocompatability complex ( MHC ) identical relate donor 1 following : Primary refractory acute myelogenous leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) AML ALL beyond first remission Therapyrelated AML stage Philadelphia chromosome ( bcrabl ) positive p190positive ALL stage Acute leukemia stage arise myelodysplastic syndrome myeloproliferative disorder , include follow : Chronic myelomonocytic leukemia Chronic myelogenous leukemia Polycythemia vera Essential thrombocytosis Agnogenic myeloid metaplasia myelofibrosis Refractory anemia excess blast Refractory anemia excess blast transformation NOTE : *Patients must enrol study prior undergoing transplantation Relapsed disease posttransplantation , evidence 1 follow criterion : Morphologic relapse , define 1 following : Peripheral blast absence growth factor therapy Bone marrow blast &gt; 5 % nucleated cell Extramedullary chloroma granulocytic sarcoma Flow cytometric relapse , define appearance cell abnormal immunophenotype consistent leukemia relapse peripheral blood bone marrow ( detected transplantation ) Cytogenetic relapse , define appearance 1 metaphase bone marrow peripheral blood cell either nonconstitutional cytogenetic abnormality detect least 1 cytogenetic study perform transplantation OR new abnormality know associate leukemia Molecular relapse , define 1 following : 1 positive polymerase chain reaction ( PCR ) assay clonotypic immunoglobulin heavy chain Tcell receptor gene rearrangement patient transplant B Tcell ALL respectively 1 positive posttransplantation reverse transcription PCR assay p190 BCRABL mRNA fusion transcript patient transplant Philadelphia chromosomepositive p190positive ALL No grade III IV acute graftversushost disease ( GVHD ) ** No extensive chronic GVHD** NOTE : **At time posttransplant relapse PATIENT CHARACTERISTICS : Age 14 ( patient &lt; 14 year age may eligible deemed sufficient height weight pediatric attend physician ) Performance status Karnofsky 60100 % ( time posttransplant relapse ) Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other No preexist major nonhematopoietic organ toxicity â‰¥ grade 3 ( time posttransplant relapse ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Concurrent immunosuppressive steroid therapy GVHD allow provide follow true : Able taper steroid dose &lt; 0.5 mg/kg/day No increase &gt; 1 grade acute GVHD OR progression chronic GVHD within 14 day dose change Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>